Condition (MeSH)
Dysgeusia
ClinicalTrials.gov lists 52 trials for Dysgeusia or a narrower condition beneath it. Hospital Sultanah Bahiyah has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
52 of the 52 trials are tagged with Dysgeusia itself; the rest are tagged with a narrower condition beneath it.
When did Dysgeusia trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2024 | 7 |
| 2023 | 3 |
| 2022 | 8 |
| 2021 | 1 |
| 2020 | 8 |
| 2019 | 5 |
| 2018 | 1 |
| 2017 | 3 |
| 2016 | 2 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Dysgeusia trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 2 |
| Phase 4 | 1 |
| Not applicable | 23 |
| Observational | 23 |
How many Dysgeusia trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 7 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 30 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Dysgeusia trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Hospital Sultanah Bahiyah | 2 |
| Ankara Etlik City Hospital | 1 |
Which drugs are being tested for Dysgeusia? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cannabidiol | 1 |
| Semaglutide | 1 |
| Talactoferrin | 1 |
| Miracle Fruit | 1 |
| Lactoferrin Bovine | 1 |
Showing 5 of 6 drugs.
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Taste Test | 1 |
| Zinc Sulfate 220 MG | 1 |
| theophylline SR | 1 |
| Oral Zinc | 1 |
| Exercise | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Dysgeusia? (54)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. | Clinical pharmacokinetics | 2024 | Yes |
| The nutritional impact of metallic taste in head and neck cancer patients: explorations and clinical implications. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2024 | Yes |
| Long-Term Dysfunction of Taste Papillae in SARS-CoV-2. | NEJM evidence | 2023 | Yes |
| Risk Factors for Olfactory and Gustatory Dysfunctions in Patients with SARS-CoV-2 Infection. | Neuroepidemiology | 2021 | Yes |
| Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. | Annals of clinical and translational neurology | 2020 | Yes |
Showing 5 of 54 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.